Skip to main content

Advertisement

Table 3 Final main effects linear model of the association between baseline explanatory variables and day 7 lumefantrine concentration in ng/mL (433 patients).

From: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Variable Coefficient 95%CI p-value p-value (trend)
   lower upper   
referred from hospital OPD (vs. from outlying clinics) -198.3 -316.9 -63.1 0.005  
unsupervised treatment -463.3 -536.8 -381.0 <0.0001  
age      
   ≥15 years [reference]     <0.0001
   5–14 years -54.6 -233.3 158.4 0.591  
   <5 years -357.9 -483.8 -208.6 <0.0001  
lumefantrine dose (mg/Kg)      
   ≥80 [reference]     0.375
   65–79 -168.6 -319.3 9.1 0.062  
   50–64 -187.5 -348.4 5.1 0.056  
   <50 -36.1 -287.0 286.8 0.806  
gametocytaemic at inclusion 395.2 89.5 775.7 0.009  
history of dizziness at inclusion -284.4 -414.9 -131.1 0.001  
constant      
    adjusted R2: 0.219
    p-value for goodness of fit: <0.0001